Affiliation:
1. Department of Hematology Oncology University of Pennsylvania Philadelphia Pennsylvania USA
Abstract
AbstractDiffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical outcomes. Our understanding of its molecular makeup continues to improve risk stratification, and artificial‐intelligence and ctDNA‐based analyses have the potential to enhance risk assessment and disease monitoring. R‐CHOP and Pola‐R‐CHP are used in the frontline setting; chimeric antigen receptor therapy (CART) is now the new standard‐of‐care for most with primary refractory disease; both CART and autologous stem cell transplantation are utilized in the relapsed and refractory setting. In this review, we summarize the classification and management of DLBCL with an emphasis on recent advances in the field.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献